Bristol Myers Squibb (BMY)

[chmcnfunds]

FOMO is bad for you. Seems like BMY has been propped up primarily by buy-out rumors only.

Also, could be low expectations from the AACR:

From Fly:

_____________________________________________-
Before the Move: Stocks to watch into meeting of cancer researchers This year's American Association for Cancer Research, or AACR, annual meeting will take place in Washington D.C. from April 1-5. Several companies are expected to present updates and new data from ongoing studies during the event. AACR ANNUAL MEETING: The AACR annual meeting 2017 will take place on April 1-5 in Washington D.C. and is expected to highlight the best cancer science and medicine from institutions all over the world. Attendees are invited to form collaborations, attend sessions outside their own areas of expertise and learn how to apply new concepts, tools and techniques to their own research, the organization has stated. DATA MAY FAVOR INCYTE: In a research note to investors ahead of the AACR meeting, BMO analyst Alex Arfaei said that the focus will be on Bristol-Myers Squibb's (BMY) Opdivo in combination with an investigational, optimized, once-daily IDO-1 inhibitor and whether the data supports its "best in class" claim. The analyst told investors that he doubts the data will appear better than Merck's (MRK) Keytruda + Incyte's (INCY) Epacadostat. Although Incyte maintains a two-year lead on other IDO-1 players, Arfaei noted that he expects the company's shares to be sensitive to clinical results for Bristol-Myers' BMS-986205 and NewLink Genetics' (NLNK) Indoximob. Overall, the analyst argued that the data at AACR are unlikely to show which IDO-1 is better, but that may be enough for Incyte since it was the first. Additionally, he believes a cost-sharing agreement with Merck and Phase 2 of Epacadostat + Keytruda in multiple solid tumor at the American Society of Clinical Oncology annual meeting remain near-term drivers of Incyte's shares.

Read more at:
http://thefly.com/landingPageNews.php?id=2528101

BMY